AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
21 Mar 2013 07:00 AM
RNS
AstraZeneca outlines growth strategy
18 Mar 2013 01:00 PM
RNS
AstraZeneca to establish strategic R&D centres
14 Mar 2013 10:00 AM
RNS
Block Listing Application
05 Mar 2013 07:00 AM
RNS
Australian court holds crestor patents invalid
01 Mar 2013 04:00 PM
RNS
Total Voting Rights
27 Feb 2013 10:00 AM
RNS
Director/PDMR Shareholding
27 Feb 2013 10:00 AM
RNS
Director/PDMR Shareholding
27 Feb 2013 10:00 AM
RNS
Director/PDMR Shareholding
27 Feb 2013 10:00 AM
RNS
Director/PDMR Shareholding
01 Feb 2013 04:00 PM
RNS
Total Voting Rights
31 Jan 2013 07:00 AM
RNS
Final Results
31 Jan 2013 07:00 AM
RNS
Final Results
30 Jan 2013 09:00 AM
RNS
Notice of Results
15 Jan 2013 01:00 PM
RNS
Announces changes to Senior Executive Team
02 Jan 2013 04:00 PM
RNS
Total Voting Rights
28 Dec 2012 03:58 PM
RNS
Director/PDMR Shareholding
14 Dec 2012 05:56 PM
RNS
CRESTOR US Patent Upheld
13 Dec 2012 02:59 PM
RNS
Top-line results of OSKIRA-4
07 Dec 2012 02:30 PM
RNS
Director/PDMR Shareholding
06 Dec 2012 02:30 PM
RNS
Director/PDMR Shareholding
03 Dec 2012 03:00 PM
RNS
Total Voting Rights
03 Dec 2012 03:00 PM
RNS
Blocklisting Interim Review
22 Nov 2012 02:30 PM
RNS
Director/PDMR Shareholding
21 Nov 2012 02:30 PM
RNS
Director/PDMR Shareholding
15 Nov 2012 04:30 PM
RNS
Director/PDMR Shareholding
14 Nov 2012 04:49 PM
RNS
FORXIGA first in class SGLT2 gets EU approval
12 Nov 2012 04:30 PM
RNS
Definition of Core Financial Measures
12 Nov 2012 07:00 AM
RNS
Top-line phase III results for Naloxegol
01 Nov 2012 03:00 PM
RNS
Total Voting Rights
29 Oct 2012 01:10 PM
RNS
Director/PDMR Shareholding
29 Oct 2012 01:10 PM
RNS
Director/PDMR Shareholding
25 Oct 2012 07:00 AM
RNS
3rd Quarter Results
24 Oct 2012 09:00 AM
RNS
Notice of Results
01 Oct 2012 04:30 PM
RNS
Total Voting Rights
01 Oct 2012 02:00 PM
RNS
AstraZeneca suspends share repurchase programme
26 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
25 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
19 Sep 2012 08:48 AM
RNS
Transaction in Own Shares
18 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
17 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
14 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
12 Sep 2012 07:00 AM
RNS
AstraZeneca prices a $2 billion bond issue
11 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
10 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
07 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
06 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
05 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
04 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
03 Sep 2012 04:00 PM
RNS
Total Voting Rights
03 Sep 2012 07:00 AM
RNS
Transaction in Own Shares
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100